Apollo Hospitals Enterprise Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹7,615 Cr +23% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AH

Apollo Hospitals Enterprise Ltd

Q3 FY26Healthcare Services

Apollo Hospitals Enterprise Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹6,477Cr
+17.2% YoY
+4.7% QoQ
Net profit
₹516Cr
+36.1% YoY
+4.5% QoQ
Margin
15%
+1 pp YoY
0 pp QoQ
Price₹8,693
Market cap₹1.3L Cr
P/E61.0

The short version

Platform GMV growth guidance: Around 30-35% year-on-year for the full year FY '26, excluding IP/OP GMV. Platform GMV is expected to grow around 30% this financial year and about 30% next year excluding IP/OP contributions.

From Apollo Hospitals Enterprise Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Platform GMV growth guidance: Around 30-35% year-on-year for the full year FY '26, excluding IP/OP GMV.
  • Hospital business revenue growth: Existing hospitals expected to grow at 12-14%, with additional beds adding another 3-4%.
  • Pharmacy physical stores: Targeting ~600 new store additions per year, with same-store growth at about 16-18%, driven by private label and store refresh initiatives.
  • Digital business (online pharmacy): GMV growing at about 30%, with an expected trajectory of 20-22% annual growth to reach INR62 billion by Q4 FY '27.

2 more points from Apollo Hospitals Enterprise Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Apollo Hospitals Enterprise Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • 1,500 new hospital beds to be added over the next year, with 50% (750 beds) operationalized in the coming year and the remaining 750 beds thereafter.
  • Breakeven expected on 1,300 new beds within 2 years.
  • Operationalization phased: 40-50% of beds expected to be operationalized by Q1, including facilities in Calcutta, Hyderabad, Pune, Sarjapur; Gurugram beds expected by Q2 due to delays.

2 more points from Apollo Hospitals Enterprise Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Apollo Hospitals Enterprise Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Apollo Hospitals Enterprise Ltd said on order book & pipeline — free account, 30 seconds.

Apollo Hospitals Enterprise Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Apollo Hospitals Enterprise Ltd Q3 FY26 results — key figures

Apollo Hospitals Enterprise Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue6,4775,527+17.2%6,189+4.7%
Operating profit (EBITDA)965762+26.6%924+4.4%
Operating margin15%14%+1 pp15%0 pp
Profit before tax682536+27.2%675+1%
Net profit (PAT)516379+36.1%494+4.5%
EPS (₹)34.9325.89+34.9%33.19+5.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.6K Cr, net profit ₹660 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q3 FY26)

    FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —

  • Aster DM Quality (Q3 FY26)

    Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…

  • Chandan Healthca (Q3 FY26)

    The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…

  • Rainbow Childrens Medicare (Q3 FY26)

    Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Apollo Hospitals Enterprise Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Apollo Hospitals Enterprise Ltd Q3 FY26 results?

Platform GMV growth guidance: Around 30-35% year-on-year for the full year FY '26, excluding IP/OP GMV. Platform GMV is expected to grow around 30% this financial year and about 30% next year excluding IP/OP contributions.

What is Apollo Hospitals Enterprise Ltd share price analysis?

Apollo Hospitals Enterprise Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹128,263 Cr. Investors should review the full earnings analysis for detailed insights.

Is Apollo Hospitals Enterprise Ltd planning capital expenditure?

1,500 new hospital beds to be added over the next year, with 50% (750 beds) operationalized in the coming year and the remaining 750 beds thereafter.

Keep Apollo Hospitals Enterprise Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.